mTOR inhibition beyond rapalogs

B. Markman, V. Serra, J. Tabernero

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.
Original languageEnglish
Title of host publicationmTOR Inhibition for Cancer Therapy
Subtitle of host publicationPast, Present and Future
EditorsMonica Mita, Alain Mita, Eric K. Rowinsky
Place of PublicationParis France
PublisherSpringer
Pages251 - 27
Number of pages25
ISBN (Electronic)978-2-8178-0492-7
ISBN (Print)978-2-8178-0491-0
DOIs
Publication statusPublished - 2016

Cite this

Markman, B., Serra, V., & Tabernero, J. (2016). mTOR inhibition beyond rapalogs. In M. Mita, A. Mita, & E. K. Rowinsky (Eds.), mTOR Inhibition for Cancer Therapy: Past, Present and Future (pp. 251 - 27). Paris France: Springer. https://doi.org/10.1007/978-2-8178-0492-7
Markman, B. ; Serra, V. ; Tabernero, J. / mTOR inhibition beyond rapalogs. mTOR Inhibition for Cancer Therapy: Past, Present and Future. editor / Monica Mita ; Alain Mita ; Eric K. Rowinsky. Paris France : Springer, 2016. pp. 251 - 27
@inbook{3ec2691b2de241b3933e8cc7e47bfa77,
title = "mTOR inhibition beyond rapalogs",
abstract = "The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.",
author = "B. Markman and V. Serra and J. Tabernero",
year = "2016",
doi = "10.1007/978-2-8178-0492-7",
language = "English",
isbn = "978-2-8178-0491-0",
pages = "251 -- 27",
editor = "Monica Mita and Alain Mita and Rowinsky, {Eric K.}",
booktitle = "mTOR Inhibition for Cancer Therapy",
publisher = "Springer",

}

Markman, B, Serra, V & Tabernero, J 2016, mTOR inhibition beyond rapalogs. in M Mita, A Mita & EK Rowinsky (eds), mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer, Paris France, pp. 251 - 27. https://doi.org/10.1007/978-2-8178-0492-7

mTOR inhibition beyond rapalogs. / Markman, B.; Serra, V.; Tabernero, J.

mTOR Inhibition for Cancer Therapy: Past, Present and Future. ed. / Monica Mita; Alain Mita; Eric K. Rowinsky. Paris France : Springer, 2016. p. 251 - 27.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - mTOR inhibition beyond rapalogs

AU - Markman, B.

AU - Serra, V.

AU - Tabernero, J.

PY - 2016

Y1 - 2016

N2 - The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.

AB - The development of therapeutic agents targeting the PI3K/Akt/mTOR pathway has been gaining momentum. The rapalogs are the most established group. New drug classes are emerging including those with single targets, those affecting multiple isoforms, and those seeking to inhibit multiple nodes within the signalling cascade. Data from clinical trials is contributing to the knowledge base of these novel compounds and is also posing further questions and challenges. Anti-cancer activity is being described but the overall response rates are lower than anticipated fuelling the need to better select patients and enrich target populations. Biomarkers are being utilized to achieve these aims and also to ensure desired pathway inhibition is occurring. Toxicities have been manageable and reversible in most cases. The next wave of studies is exploring PI3K/Akt/mTOR inhibitors administered in combination with hormones, cytotoxics, or other targeted therapies, amongst others. This chapter reviews the different classes of drugs in development as well as the pertinent findings from these clinical trials.

UR - http://link.springer.com/book/10.1007%2F978-2-8178-0492-7

U2 - 10.1007/978-2-8178-0492-7

DO - 10.1007/978-2-8178-0492-7

M3 - Chapter (Book)

SN - 978-2-8178-0491-0

SP - 251

EP - 227

BT - mTOR Inhibition for Cancer Therapy

A2 - Mita, Monica

A2 - Mita, Alain

A2 - Rowinsky, Eric K.

PB - Springer

CY - Paris France

ER -

Markman B, Serra V, Tabernero J. mTOR inhibition beyond rapalogs. In Mita M, Mita A, Rowinsky EK, editors, mTOR Inhibition for Cancer Therapy: Past, Present and Future. Paris France: Springer. 2016. p. 251 - 27 https://doi.org/10.1007/978-2-8178-0492-7